Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

No benefit to trastuzumab after progression in HER2-positive gastric, GEJ cancers

Key clinical point: Second-line treatment with paclitaxel plus trastuzumab didn’t improve progression-free survival, compared with paclitaxel alone, in patients with HER2-positive advanced gastric or gastroesophageal junction cancers who progressed on trastuzumab.

Major finding: The median progression-free survival was 3.2 months in the paclitaxel arm and 3.7 months in the paclitaxel/trastuzumab arm (P = .33).

Study details: A randomized, phase 2 study of 91 patients.

Disclosures: Partial support for the study came from a Japan Society of Clinical Oncology grant program. The authors disclosed relationships with Chugai Pharma, Lilly, Takeda, and numerous other companies.

Citation:

Makiyama A et al. J Clin Oncol. 2020 Mar 24. doi: 10.1200/JCO.19.03077.